SCHEMBL30278546

SCHEMBL30278546

CC1(C)CCC(c2ccc(-c3nccs3)c(C(F)(F)F)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 1/20 0.38
▸ P2RX7 Q99572 2/20 0.36
▸ APP P05067 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ HCRTR1 O43613 1/20 0.34
▸ HCRTR2 O43614 1/20 0.34
▸ DRD2 P14416 3/20 0.32
▸ DRD3 P35462 3/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ CHRNA7 P36544 1/20 0.32
▸ HTR3A P46098 1/20 0.32
▸ SRC P12931 1/20 0.32
▸ ZAP70 P43403 1/20 0.32
▸ SYK P43405 1/20 0.32
▸ RBP4 P02753 1/20 0.32
▸ F2RL1 P55085 1/20 0.31
▸ PDK2 Q15119 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25763098 0.76 POLQ (0.39) APPCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL30278452 0.72 S1PR1 (0.36) S1PR1P2RX7SRCZAP70SYK
SCHEMBL30278504 0.70 S1PR1 (0.43) S1PR1P2RX7SRCZAP70SYK
SCHEMBL25073212 0.68 EIF4E (0.41) APPCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10586520 0.67 S1PR1 (0.43) S1PR1P2RX7HCRTR1HCRTR2SRC
SCHEMBL3058083 0.66 ALDH1A1 (0.51) S1PR1P2RX7CYP3A4CYP2D6CYP2C19
SCHEMBL28284336 0.66 RORC (0.42) S1PR1P2RX7HCRTR1HCRTR2
SCHEMBL25763097 0.65 POLQ (0.38) DRD2DRD3CHRNA7PDK2POLQ
SCHEMBL30278485 0.65 DRD4 (0.36) CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL26373483 0.64 POLQ (0.35) S1PR1PDK2POLQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376452-A1 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof ENANTA PHARM INC (US) 2025-12-11 — — US disclosed
US-12384753-B2 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2025-08-12 — — US disclosed
EP-4387603-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF Enanta Pharmaceuticals, Inc. (US) 2024-06-26 — — EP disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 S1PR1 2072/4885P2RX7 4720/4885APP 2042/4885
US-20250376452-A1 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof HSD17B1, HSD17B13, HSD17B3 S1PR1 2072/4885P2RX7 4720/4885APP 2042/4885
US-12384753-B2 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof HSD17B1, HSD17B13, HSD17B3 S1PR1 2072/4885P2RX7 4720/4885APP 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback